TABLE 1.
In vitro activity of GSK2140944 and comparators against MRSA isolates utilized in the murine lung infection model
| S. aureus isolate | Characteristic(s)a | MIC (mg/liter) |
||
|---|---|---|---|---|
| GSK2140944 | Levofloxacin | Linezolid | ||
| 456 | VRSA | 0.125 | 32 | 1 |
| 508 | MRSA | 0.25 | 0.125 | 4 |
| F40-14 | MRSA | 0.25 | >32 | 1 |
| 146 | USA300, PVL(+), SCCmec IV, CA-MRSA | 0.5 | 8 | 2 |
| 156 | USA300, PVL(−), spa type 1, SCCmec IV, CA-MRSA | 0.5 | 8 | 4 |
| 509 | USA300, PVL(+), CA-MRSA | 0.5 | 0.125–0.25 | 2–4 |
a
VRSA, vancomycin-resistant S. aureus; MRSA, methicillin-resistant S. aureus; PVL(+), produces Panton-Valentine leukocidin; PVL(−), does not produce PVL; SCCmec IV, staphylococcal cassette chromosome mec type IV; CA-MRSA, community-acquired methicillin-resistant S. aureus.